FDA starts the priority review clock for Symbiomix; Cornerstone gets a green light on pivotal studies
→ The FDA accepted Symbiomix’s NDA for Solosec (secnidazole oral granules), an antibiotic designed to treat bacterial vaginosis, and stamped it with a priority …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
